These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25290725)

  • 21. Associations of anemia and renal dysfunction with outcomes among patients hospitalized for acute decompensated heart failure with preserved or reduced ejection fraction.
    Kajimoto K; Sato N; Keida T; Sakata Y; Takano T;
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1912-21. PubMed ID: 25183660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure.
    French B; Wang L; Ky B; Brandimarto J; Basuray A; Fang JC; Sweitzer NK; Cappola TP
    J Card Fail; 2016 Apr; 22(4):256-62. PubMed ID: 26571149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure.
    Christenson RH; Duh SH; Wu AH; Smith A; Abel G; deFilippi CR; Wang S; Adourian A; Adiletto C; Gardiner P
    Clin Biochem; 2010 May; 43(7-8):683-90. PubMed ID: 20153309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction.
    Carrasco-Sánchez FJ; Aramburu-Bodas O; Salamanca-Bautista P; Morales-Rull JL; Galisteo-Almeda L; Páez-Rubio MI; Arias-Jiménez JL; Aguayo-Canela M; Pérez-Calvo JI
    Int J Cardiol; 2013 Nov; 169(3):177-82. PubMed ID: 24207066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial.
    Edelmann F; Holzendorf V; Wachter R; Nolte K; Schmidt AG; Kraigher-Krainer E; Duvinage A; Unkelbach I; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Stough WG; Pieske BM
    Eur J Heart Fail; 2015 Feb; 17(2):214-23. PubMed ID: 25418979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
    JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.
    de Boer RA; Lok DJ; Jaarsma T; van der Meer P; Voors AA; Hillege HL; van Veldhuisen DJ
    Ann Med; 2011 Feb; 43(1):60-8. PubMed ID: 21189092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.
    Felker GM; Fiuzat M; Shaw LK; Clare R; Whellan DJ; Bettari L; Shirolkar SC; Donahue M; Kitzman DW; Zannad F; Piña IL; O'Connor CM
    Circ Heart Fail; 2012 Jan; 5(1):72-8. PubMed ID: 22016505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Galectin-3, a prognostic marker--and a therapeutic target?
    Pereira AR; Menezes Falcão L
    Rev Port Cardiol; 2015 Mar; 34(3):201-8. PubMed ID: 25746675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the Diastolic Stress Test With a Combined Resting Echocardiography and Biomarker Approach to Patients With Exertional Dyspnea: Diagnostic and Prognostic Implications.
    Kosmala W; Przewlocka-Kosmala M; Rojek A; Marwick TH
    JACC Cardiovasc Imaging; 2019 May; 12(5):771-780. PubMed ID: 29454783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Galectin-3 is related to right ventricular dysfunction in heart failure patients with reduced ejection fraction and may affect exercise capacity.
    Zaborska B; Sygitowicz G; Smarż K; Pilichowska-Paszkiet E; Budaj A
    Sci Rep; 2020 Oct; 10(1):16682. PubMed ID: 33028850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myocardial Galectin-3 Expression Is Associated with Remodeling of the Pressure-Overloaded Heart and May Delay the Hypertrophic Response without Affecting Survival, Dysfunction, and Cardiac Fibrosis.
    Frunza O; Russo I; Saxena A; Shinde AV; Humeres C; Hanif W; Rai V; Su Y; Frangogiannis NG
    Am J Pathol; 2016 May; 186(5):1114-27. PubMed ID: 26948424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
    Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
    JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure.
    Mueller T; Gegenhuber A; Leitner I; Poelz W; Haltmayer M; Dieplinger B
    Clin Chim Acta; 2016 Dec; 463():158-164. PubMed ID: 27983996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure.
    Zhang Y; Zhang R; An T; Huang Y; Guo X; Yin S; Wang Y; Ji S; Lv R; Zhang J; Maisel A
    J Card Fail; 2015 Jan; 21(1):51-9. PubMed ID: 25463412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction.
    Kanukurti J; Mohammed N; Sreedevi NN; Khan SA; Baba KSSS; Bhaskar MV; Satish OS; Naushad SM; Mohan IK
    J Lab Physicians; 2020 Aug; 12(2):126-132. PubMed ID: 32905127
    [No Abstract]   [Full Text] [Related]  

  • 37. Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis.
    Meijers WC; van der Velde AR; Ruifrok WP; Schroten NF; Dokter MM; Damman K; Assa S; Franssen CF; Gansevoort RT; van Gilst WH; Silljé HH; de Boer RA
    J Am Heart Assoc; 2014 Sep; 3(5):e000962. PubMed ID: 25237044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction.
    Gurwitz JH; Magid DJ; Smith DH; Goldberg RJ; McManus DD; Allen LA; Saczynski JS; Thorp ML; Hsu G; Sung SH; Go AS
    Am J Med; 2013 May; 126(5):393-400. PubMed ID: 23499328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heart failure with preserved left ventricular ejection fraction in patients with acute myocardial infarction.
    Antonelli L; Katz M; Bacal F; Makdisse MR; Correa AG; Pereira C; Franken M; Fava AN; Serrano Junior CV; Pesaro AE
    Arq Bras Cardiol; 2015 Aug; 105(2):145-50. PubMed ID: 26039659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diagnostic Value of Biochemical Markers in Patients With Chronic Heart Failure With Reduced, Borderline and Preserved Left Ventricular Ejection Fraction].
    Bazaeva EV; Myasnikov RP; Metelskaya VA; Boytsov SA
    Kardiologiia; 2017 Mar; 57(3):39-45. PubMed ID: 28762934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.